• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

    8/27/25 8:05:00 AM ET
    $MNKD
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email

    DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD) today announced that United Therapeutics Corporation (NASDAQ:UTHR) has exercised its option—granted under the companies' 2018 license and collaboration agreement—to develop a second dry powder inhalation therapy.

    The original agreement, which led to U.S. FDA approval of Tyvaso DPI in May 2022, included an option for United Therapeutics to expand the license to include additional active ingredients. Under the terms of the expanded agreement, MannKind will formulate a second investigational molecule using its proprietary Technosphere® platform, and United Therapeutics will conduct preclinical and clinical development.

    "Building on the success of Tyvaso DPI, we are proud to deepen our collaboration with United Therapeutics to bring innovative patient-centric inhaled therapies to patients living with pulmonary hypertension," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "This next step highlights the strength of our partnership and the versatility of our dry powder formulations and inhalation devices in addressing serious respiratory conditions."

    Under the terms of the expanded agreement, MannKind will receive an upfront payment of $5 million and is eligible to receive up to $35 million in development milestones and 10% royalties on net sales of any resulting product.

    Formulation and development activities for the new investigational molecule will begin immediately.

    About MannKind

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

    We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

    With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

    Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

    Forward-Looking Statements

    Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding the potential development of an investigational product and receipt of milestone payments and royalties. Words such as "believes", "anticipates", "plans", "expects", "intends", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that continued testing of an investigational drug product may not yield successful results or results that are consistent with earlier testing, and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

    TYVASO DPI is a registered trademark of United Therapeutics Corporation.

    TECHNOSPHERE and MANNKIND are registered trademarks of MannKind Corporation.



    MannKind Contacts:
    Investor Relations
    Ana Kapor, (818) 661-5000
    Email: [email protected]
    
    Media Relations
    Christie Iacangelo, (818) 292-3500
    Email: [email protected]

    Primary Logo

    Get the next $MNKD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNKD
    $UTHR

    CompanyDatePrice TargetRatingAnalyst
    United Therapeutics Corporation
    $UTHR
    10/20/2025$414.00Underweight
    Wells Fargo
    MannKind Corporation
    $MNKD
    10/20/2025$10.00Overweight
    Wells Fargo
    MannKind Corporation
    $MNKD
    10/10/2025$9.00Outperform
    Leerink Partners
    United Therapeutics Corporation
    $UTHR
    9/26/2025$569.00Outperform
    RBC Capital Mkts
    MannKind Corporation
    $MNKD
    7/16/2025$9.00Buy
    H.C. Wainwright
    United Therapeutics Corporation
    $UTHR
    6/2/2025$405.00Overweight
    Cantor Fitzgerald
    United Therapeutics Corporation
    $UTHR
    4/25/2025Overweight → Equal Weight
    Wells Fargo
    United Therapeutics Corporation
    $UTHR
    4/21/2025$314.00Underperform → Neutral
    BofA Securities
    More analyst ratings

    $MNKD
    $UTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on United Therapeutics with a new price target

    Wells Fargo initiated coverage of United Therapeutics with a rating of Underweight and set a new price target of $414.00

    10/20/25 8:04:30 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Mannkind with a new price target

    Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $10.00

    10/20/25 8:01:49 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Mannkind with a new price target

    Leerink Partners initiated coverage of Mannkind with a rating of Outperform and set a new price target of $9.00

    10/10/25 8:38:42 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 29, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision an

    10/15/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

    If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026 WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) seeking approval for Afrezza (insulin human) Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes. The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of Ma

    10/13/25 8:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest Physicians taking place October 19-22, 2025, in Chicago. In addition, United Therapeutics will sponsor and host several events including the PHinding Pulmonary Hypertension: Exploring Best Practices in PH-ILD Detection and Management dinner symposium and the Women in Chest Medicine Annual Luncheon. "CHEST is a powerful platform for United Therapeutics and the pulmonary hypertension community to connect, share new developments, and elevate patient care," said Andrew Nelsen, PharmD, VP of Global Medi

    10/13/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    11/8/24 4:30:29 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by United Therapeutics Corporation

    SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    10/16/24 1:03:48 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    6/10/24 12:15:17 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairperson & CEO Rothblatt Martine A exercised 8,000 shares at a strike of $120.26 and sold $3,399,650 worth of shares (8,000 units at $424.96) (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    10/22/25 5:54:30 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND COO Benkowitz Michael sold $9,616,702 worth of shares (22,500 units at $427.41) and exercised 22,500 shares at a strike of $139.13 (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    10/21/25 4:30:29 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairperson & CEO Rothblatt Martine A sold $3,421,037 worth of shares (8,000 units at $427.63) and exercised 8,000 shares at a strike of $120.26 (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    10/20/25 4:31:44 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    SEC Filings

    View All

    SEC Form 144 filed by United Therapeutics Corporation

    144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    10/24/25 3:49:01 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by United Therapeutics Corporation

    144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    10/21/25 4:36:03 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by United Therapeutics Corporation

    144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    10/16/25 4:02:12 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    Financials

    Live finance-specific insights

    View All

    United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 29, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision an

    10/15/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

    Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals' 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals' closing price on August 22, 2025Strengthens organization by integrating scPharmaceuticals

    8/25/25 7:30:00 AM ET
    $MNKD
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

    2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD 2024Advanced pipeline: Submitted sBLA for Afrezza® in pediatric populationMNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of scheduleMNKD-201: Plan to initiate Phase 2 clinical trial for IPF by YE 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the second quarter 2025 and provided a business update. "The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes," said Mi

    8/6/25 7:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    Leadership Updates

    Live Leadership Updates

    View All

    MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today. Dr. Ahuja will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company's executive leadership team. "Ajay's deep expertise in medical affairs, clinical development, and global strategy—combined with his background as a practicing physician—will be instrumental as we continue to advance o

    9/29/25 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

    MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

    1/5/22 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

    WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

    1/27/21 8:00:00 AM ET
    $CLGN
    $UTHR
    $XERS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations